Advances in Specific Immunotherapy for Prostate Cancer

Slides:



Advertisements
Similar presentations
Chapter15 B cell mediated immune response. B cells mediated immune response Humoral immunity(HI) or antibody mediated immunity: The total immunological.
Advertisements

Immunology in Head and Neck Cancer Stephanie Cordes, MD Christopher Rassekh, MD February 11, 1998.
T cell-mediated immunity Chapter 8
Adaptive Defenses T Lymphocytes T lymphocytes constitute the "cellular" arm of acquired/specific immunity T lymphocytes play a central role in controlling.
Copyright © 2006 Pearson Education, Inc., publishing as Benjamin Cummings Chapter 14 Specific Immunity (adaptive immunity)
General classes of vaccines An induced mobilization of the immune response for the purpose of therapeutic benefit. Preventative: infectious agents Therapeutic:
Review: Cells of the Immune System Leukocytes – White blood cells Myelocytes –macrophage, neutrophil, eosinophil,basophil Leukocytes – B, T and NK cells.
Tumor immunotherapy 张沛张书铭 张黎明 赵宸 赵世刚 Tumour Immunotherapy: questions Can immune stimulators combat cancer? Which forms of immunotherapy can be used?
T -lymphocytes T cell receptor T – cytotoxic (CD8) cells
Objectives Introduction Ags expressed by cancer cells
HOST DEFENCE AGAINST TUMORS:
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma  André Veillette, Huaijian Guo  Critical Reviews.
Chapter 43 The Immune System.
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Mononuclear phagocytes in Immune Defence
Cancer and the Immune System
CELL-MEDIATED IMMUNITY RAHUL KUMAR LOHANA 2K16/MB/50 INSTITUTE OF MICROBIOLOGY UNIVERSITY OF SINDH, JAMSHORO.
Avoiding Immune Detection
Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.
Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.
Immunotherapy of hepatocellular carcinoma
Challenges in the Development of Effective Peptide Vaccines for Cancer
Specific Defenses of the Host: The Immune Response
Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers  Ivana Catacchio, Anna Scattone, Nicola.
Engineering Natural Killer Cells for Cancer Immunotherapy
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
T cell mediated immunity
Cancer Immunotherapy by Dendritic Cells
Differentiation and Functions of CD8+ Effector T Cells
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
The cellular immune response to cancer is complex and involves a diverse repertoire of immunoregulatory interactions principally involving antigen presenting.
Chapter 13 Effector Responses
Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial  Max Heckler, Stephanie.
Prostate Cancer Detection: A View of the Future
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Malaria Vaccine Design: Immunological Considerations
Colorectal cancer vaccines: Principles, results, and perspectives
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Chapter 13 Effector Responses Dr. Capers
Volume 50, Issue 5, Pages (November 2006)
Laurence Zitvogel, Guido Kroemer  Cancer Cell 
N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R
Engineering Natural Killer Cells for Cancer Immunotherapy
AllergoOncology: IgE- and IgG4-mediated immune mechanisms linking allergy with cancer and their translational implications  Erika Jensen-Jarolim, MD,
Robert J Korst, MD, Ronald G Crystal, MD 
Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors  Sara Charmsaz, Andrew M. Scott,
Volume 3, Issue 5, Pages (May 2003)
HCMV jogs the ‘memory’ of NK cells in HBV
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against Autologous Malignant Cells in Sezary Syndrome Patients  Jean-David Bouaziz,
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
Tumor immunology.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology—Thirty Years of Progress but Still Much to Be Done 
Albert J. Czaja, Michael P. Manns  Gastroenterology 
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
N. Clementi, F. Cappelletti, E. Criscuolo, M. Castelli, N. Mancini, R
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
The F-box protein Fbxw7 is required for maintenance of normal stem cells. Figure 1 from S Takeishi British Journal of Cancer (2014) 111, ; doi: /bjc
Releasing the Brakes on Cancer Immunotherapy
Vaccines for Lung Cancer
Dendritic-Cell-Based Therapeutic Cancer Vaccines
by Jennifer Couzin-Frankel
Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.
Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)
BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.
Presentation transcript:

Advances in Specific Immunotherapy for Prostate Cancer Andrea Kiessling, Susanne Füssel, Rebekka Wehner, Michael Bachmann, Manfred P. Wirth, E. Peter Rieber, Marc Schmitz  European Urology  Volume 53, Issue 4, Pages 694-708 (April 2008) DOI: 10.1016/j.eururo.2007.11.043 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Current T-cell– and antibody-based strategies in immunotherapy of prostate cancer. Tumor-specific T-cell responses can be induced by vaccination. Tumor peptides, tumor proteins, or cDNA coding for tumor antigens are administered to the patient. Being taken up by DCs in vivo they are presented to T cells in regional lymph nodes. Alternatively, DCs are loaded ex vivo with the respective tumor antigen preparation and injected into the patient as DC vaccine. DCs can efficiently activate CD8+ CTLs, which are capable of recognizing and destroying tumor cells. They can also stimulate CD4+ T cells, which increase the capacity of DCs to induce CD8+ CTLs through the interaction of CD40 ligand on CD4+ cells and the CD40 receptor on DCs. In addition, CD4+ T cells support the expansion and maintenance of CD8+ CTLs by secreting cytokines such as IL-2 and are themselves capable of killing tumor cells. Monoclonal antibodies directed against tumor surface antigens can mediate cytolysis either by engaging cytotoxic effector cells such as NK cells via Fc receptors (ADCC) or by complement activation. Toxins or radioisotopes when coupled to monoclonal antibodies can specifically be targeted to tumor cells. Recombinant bispecific antibody constructs directed against a tumor cell surface antigen and an activating receptor on immune effector cells can polyclonally engage these cells into tumor eradication. ADCC=antibody-dependent cellular cytotoxicity; CTLs=cytotoxic T cells; DCs=dendritic cells; HLA=human leukocyte antigen; IL=interleukin; NK=natural killer; TCR=T-cell receptor. European Urology 2008 53, 694-708DOI: (10.1016/j.eururo.2007.11.043) Copyright © 2007 European Association of Urology Terms and Conditions